Here is my consolidated final review, verified directly against the paper text.

---

## Summary

This paper introduces FILTER, an AI tool that integrates property prediction, Siamese Network embedding-based pathway inference, and molecular docking to evaluate candidate antibiotics generated through fragment-based retrosynthesis. The authors present three in silico experiments — retrosynthetic analysis of penicillin derivatives, hybrid antibiotic design from multiple classes, and chemical space exploration of under-explored classes — to demonstrate FILTER's utility as a computational oracle for antibiotic discovery.

## Strengths

- **Predictive accuracy for key pharmacokinetic properties**: Section 4.1 documents that the combined NN+XGBoost model achieves ROC AUC 0.9104, precision 0.9653, recall 0.8385, and F1 0.8975 for bioavailability prediction, demonstrating reliable classification of a central drug-likeness property.

- **Pathway inference from SMILES alone via SNet embeddings**: The paper describes (Section 4.2) a transfer learning setup where a model is trained to predict SNet embeddings from SMILES strings, then newly synthesized molecules are clustered with known drugs from Reactome using HDBScan. This approach enables functional pathway assignment for molecules lacking any biological data — a practical capability for prioritizing candidates.

- **Multi-source data integration**: The tool draws on DrugBank, Reactome, PDB, and ANTIV Siamese Network embeddings (Section 2.2), providing a diverse training foundation that spans chemical properties, pathway information, and protein structural data.

- **Demonstration of novel compounds with stronger predicted binding**: Section 4.3 reports docking scores for novel compounds against PBPs (13.2 vs. ampicillin's 10.2) and against JNK1 (13.4), providing evidence that FILTER can help identify molecules with enhanced predicted binding relative to known antibiotics.

## Weaknesses

### Fatal

None.

### Major

- **FILTER's core predictive models are underspecified, undermining reproducibility.** Section 2 states that FILTER uses neural networks, XGBoost, and a combined model, but provides no architectural details (layer counts, dimensions, activation functions), no loss functions, no training procedure, no hyperparameters, no data splits, and no validation strategy. Table 1 (which lists the prediction models) is referenced but the images containing model details are parser artifacts. The "select features" discussion (Rule of Five, rotatable bond count, Caco2 permeability) does not clarify whether these are inputs to the models or properties being predicted, nor how they are integrated. Without this information, FILTER is a black box and the paper's central methodological contribution cannot be independently assessed or reproduced. This is not a minor omission — it is a structural gap in the description of the paper's main contribution.

- **The three main experiments lack quantitative results in the main text, making their support of the paper's claims difficult to evaluate.** Experiment 1 (retrosynthesis of penicillin derivatives) receives no quantitative report — no count of how many historical derivatives were reproduced, no precision/recall against known synthetic routes, no comparison metric. Experiment 2 (hybrid antibiotics) similarly provides no library size, no docking scores for hybrid molecules, and no comparison to single-class antibiotics. Experiment 3 (under-explored classes) reports one docking score (13.4 against JNK1) but no distribution, no clustering statistics, no library size. The paper repeatedly defers to tables in the appendix (Tables 3, 4; Figure 4), which exist in the original submission but whose key summary statistics should appear in the main text. As published, the central experimental claims are not substantiated by visible evidence.

- **No comparison to existing tools or baselines.** The paper positions FILTER as a tool for property prediction and antibiotic candidate evaluation, yet provides no comparison to standard baselines (e.g., RDKit descriptors + Random Forest, ChemProp, or MoleculeNet benchmarks, which the paper itself cites). Without such comparison, the reader cannot assess whether FILTER adds value over off-the-shelf methods — the paper's core utility claim is ungrounded. This is a critical omission for a tool paper.

- **Docking validation is minimal and lacks statistical rigor.** Section 4.3 reports a single docking score for one novel compound (13.2 vs. ampicillin's 10.2). No standard deviation, no distribution over multiple runs, no negative controls (e.g., non-antibiotic molecules to establish a baseline). The claim that "top candidates show scores comparable to those of known penicillin-class antibiotics" rests on a single example. Additionally, the docking is performed only against *E. coli* PBPs, but the paper's framework claims generality ("evaluate any protein target associated with an antibiotic class") without demonstrating that generality. This does not invalidate the approach but limits the strength of the evidence.

### Minor

- **The paper claims semi-supervised learning (Sections 2.1, 5) but never describes any semi-supervised methodology.** The paper states "employing semi-supervised learning, we compensate for the lack of labeled data" (line 42) and refers to "our semi-supervised learning model" (line 171), yet Section 2 describes only supervised models (NN, XGBoost, combined). If the SNet embeddings (learned from unlabeled graph data) are meant to constitute the semi-supervised component, this should be stated explicitly. As written, the claim is unsupported.

- **The paper overclaims relative to evidence.** The Conclusion (Section 6) describes FILTER as "effectively bridging the gap between chemical structure and biological function" and "an invaluable asset," and states the approach "set a new standard for the rapid, efficient, and innovative exploration of therapeutic compounds." These claims far exceed what the limited quantitative evidence can support. The tone should be calibrated to the actual scope of the findings.

- **Dataset preprocessing details are omitted.** Section 2.2 lists four datasets but provides no information on how they were preprocessed, merged, or split for training/validation. The ANTIV SNet multigraph (drug-protein and protein-protein interactions) is described at a high level but its size, coverage, and construction method are not given. These are standard details needed for reproducibility.

- **Clustering analysis is purely qualitative.** Section 4.2 presents a t-SNE visualization (Figure 3) with no quantitative clustering metrics (silhouette score, Davies–Bouldin index, purity against known pathway labels). HDBScan parameters are not reported.

### Trivial

None that survive filtering (all minor presentation issues are parser artifacts, not author errors).

## Nice-to-Haves

- The paper mentions QuickVina 2 docking against five *E. coli* PBPs. Repeating the experiment against a broader panel of targets (e.g., Gram-positive PBPs, non-PBP targets) would strengthen the claim of generality.
- A comparison of predicted properties against known experimental measurements (where available) would ground the docking scores in real-world validity.
- The code repository is cited as available at an anonymous URL. Ensuring this link is functional and documented will be important for publication.

## Removed Points

These points are flagged to be removed; treat them with caution:

- **Criticism that appendix tables (Tables 3, 4; Figure 4) are missing.** The parser strips all appendix content from all papers; these tables exist in the original submission. The underlying criticism that the main text should *summarize* key results is kept above, but the framing that the tables are "absent" is removed.
- **Criticism about Table 1 appearing as a "garbled image."** This is a PDF-to-text parser artifact, not an author error.
- **Criticism that "antibiotic class spaces" in the title is never formally defined.** The paper defines "antibiotic space" in Section 1 as "the vast chemical landscape that emerges from the combination and modification of molecular fragments derived from existing antibiotics." This is sufficient.
- **Criticism that the "one compound outperforming ampicillin" is only one example.** The docking section does report a second value (13.4 against JNK1) and states the full results are in the appendix. The weakness about insufficient docking validation is preserved but sharpened to focus on the lack of statistical rigor rather than a count of examples alone.
- **The claim that GEN is "redacted" and the pipeline is therefore "incomplete."** GEN is cited as "Redaction (YEARa)" — standard for double-blind anonymous submissions. The paper states code and datasets are available at an anonymous URL, so the tool is available albeit anonymously. The underlying issue (that GEN is not described in the main text) is a minor concern that will be resolved when the paper is de-anonymized.
- **Strength Finder's claim #3 about "pathway inference via SNet embeddings without biological data"** — kept as a real strength. However, **Strength Finder's claim #4 about "multi-source data integration"** is generic: any tool using multiple datasets does this. Kept in Strengths but toned down.

## Novel Insights

The SNet-based pathway inference approach — training a model to predict embeddings (derived from a drug-protein interaction graph) using only SMILES strings, then clustering novel molecules with known drugs in that space — is the most methodologically novel component. If this works as described, it would enable pathway-level functional annotation for compounds without any experimental data. However, the paper does not validate this: there is no quantitative clustering metric, no ablation testing whether the predicted embeddings preserve meaningful structure, and no comparison to alternative featurization methods (Morgan fingerprints, graph neural network embeddings, etc.). The docking-integrated workflow is also useful but not novel in isolation.

## Suggestions

1. **Provide a complete specification of FILTER's models** in the main text: architecture (layer types, sizes), training procedure, data splits, hyperparameter selection method, and clarify whether Rule of Five et al. are input features or predicted properties. A single table with model specification would suffice.

2. **Bring the central quantitative results of all three experiments into the main text.** For Experiment 1: number of historical derivatives reproduced, precision/recall against known routes. For Experiment 2: library size, average docking scores, number of multi-MoA candidates. For Experiment 3: library size, docking score distribution, clustering purity. One summary table in the main text would address this.

3. **Add baseline comparisons.** Compare FILTER's property predictions to standard methods (e.g., RDKit+RF, ChemProp) on at least one common benchmark (e.g., a subset of MoleculeNet tasks). Without this, the tool's value proposition is unsubstantiated.

4. **Add statistical rigor to docking evaluation.** Report docking scores as mean ± std over multiple runs or conformations. Include known antibiotics and known non-antibiotics as positive and negative controls. Show ROC-style analysis of how well the docking oracle distinguishes known actives from inactives.

5. **Remove unsupported claims about semi-supervised learning** or explicitly describe how it is implemented. Calibrate the Conclusion's language to what the evidence actually supports.

## Score and Decision

**Originality**: The SNet embedding-based pathway inference approach is somewhat novel, but the overall pipeline (property prediction + docking) is a standard computational workflow. **Importance of question**: High — AI-accelerated antibiotic discovery is a timely and important problem. **Claims support**: Weak — insufficient quantitative evidence in the main text, no baselines, minimal docking validation. **Soundness**: Below threshold — the central method is underspecified, and the experimental results are not convincingly presented. **Clarity**: Adequate in narrative but poor in technical specifics. **Value to community**: Potentially useful if the tool is released and validated, but the current manuscript does not provide enough to assess this.

The paper presents an interesting vision and a reasonable computational pipeline, but the current manuscript does not provide enough technical specificity or quantitative evidence to be accepted. The method section must describe FILTER's models in sufficient detail for reproducibility. The experiments must present their key results in the main text, not entirely in the appendix. Baseline comparisons are essential for a tool paper. The paper would benefit from recalibrating its claims to match the evidence.

MY FINAL SCORE: <pineapple>4.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>